Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial.
Ashok Seth, Yoshinobu Onuma, Praveen Chandra...
https://pubmed.ncbi.nlm.nih.gov/31147308/Actively Recruiting
Led by Ceric Sàrl · Updated on 2026-04-30
2256
Participants Needed
1
Research Sites
169 weeks
Total Duration
This research aims to compare two Leave nothing behind strategies for treating new coronary artery lesions in patients aged 18 to 68 with Chronic Coronary Syndromes CCS or Acute Coronary Syndrome ACS, including Non-ST-segment Elevation Myocardial Infarction NSTEMI and Unstable Angina. The study evaluates whether angioplasty with a Drug-Coated Balloon DCB plus bail-out Bioresorbable Scaffold BRS has similar clinical outcomes and angiographic results compared to BRS treatment alone over both early and long-term periods. Participants are randomly assigned to one of two treatment groups one group receives angioplasty starting with lesion preparation and treatment using the Mozec SEB DCB, with bail-out BRS if needed the other group receives BRS treatment with MeRes100. Both procedures involve balloon catheter use through femoral or brachial arteries and may include Optical Coherence Tomography OCT imaging if available. Bail-out BRS is deployed carefully with specific inflation timing and pressure guidelines. The study includes an angiographic substudy to measure in-segment net gain at 13 months. Participants will be followed for up to 5 years with scheduled visits including in-hospital and telephone check-ins at 1 month, 6 months, 1 year, and annually up to 5 years. Researchers will monitor the primary outcome of target-vessel failure TVF, which includes cardiovascular death, target-vessel heart attack, or revascularization, as well as secondary outcomes like bleeding events and other adverse clinical events. The study tracks both clinical and angiographic results to assess long-term efficacy and safety.
CONDITIONS
Leave Nothing Behind Study Which Compares DCB With Bail Out BRS Versus BRS Strategy Alone
D
DAVIDE CAPODANNO, Professor
C
CERC France
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ceric Sàrl
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receive angioplasty with either drug-coated balloon (DCB) with bail-out bioresorbable scaffold (BRS) or BRS treatment alone to treat coronary artery lesions.
1 baseline angioplasty procedure and regular follow-up visits over 12 months
Duration - Up to 5 years after treatment
Participants are monitored for cardiovascular events and safety outcomes annually up to 5 years after treatment.
Annual visits for up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ashok Seth, Yoshinobu Onuma, Praveen Chandra...
https://pubmed.ncbi.nlm.nih.gov/31147308/Davide Capodanno, Dominick J Angiolillo
https://pubmed.ncbi.nlm.nih.gov/28279311/Puneet K Verma, Sanjeev Sroa, Paras Koushal
https://pubmed.ncbi.nlm.nih.gov/40114731/David A Power, Anton Camaj, Dean J Kereiakes...
https://pubmed.ncbi.nlm.nih.gov/39814482/Mahesh V Madhavan, Ajay J Kirtane, Björn Redfors...
https://pubmed.ncbi.nlm.nih.gov/32057373/Giulio G Stefanini, David R Holmes
https://pubmed.ncbi.nlm.nih.gov/23323902/Yao-Jun Zhang, Christos V Bourantas, Takashi Muramatsu...
https://pubmed.ncbi.nlm.nih.gov/24472767/Raban V Jeger, Simon Eccleshall, Wan Azman Wan Ahmad...
https://pubmed.ncbi.nlm.nih.gov/32473887/Rajendra Kumar Premchand Jain, Keyur Parikh, Selvamani Sethuraman...
https://pubmed.ncbi.nlm.nih.gov/40051667/Corrado Tamburino, Azeem Latib, Robert-Jan van Geuns...
https://pubmed.ncbi.nlm.nih.gov/25599676/Ceric Sàrl
Lead Sponsor